iThriveMD Review

The semaglutide page advertises an initial $199 payment followed by $299 every 28 days for its recurring option. Its prepaid price cards show $269.10 for the 12-week option, $254.15 for 24 weeks and $239.20 for 48 weeks as displayed periodic equivalents. The longer arrangements are marked paid upfront.

The page labels those longer plans three, six and 12 months. Their stated coverage is measured in weeks, so the 48-week option is shorter than a calendar year. Do not compare its periodic equivalent with a calendar-month plan without accounting for that difference. Ask for the exact upfront charge and the dates through which medication and care are covered.

The tirzepatide page shows $299 initially and $399 afterward for its every-28-day option. Its prepaid equivalents are $299.25 for 12 weeks, $259.35 for 24 weeks and $199.50 for 48 weeks. These are separate commitment-specific offers, not interchangeable prices for a single month.

Twelve 28-day periods equal 336 days. That arithmetic matters when forecasting a year of recurring charges or comparing a prepaid offer with a competitor. The pages also mention payment-plan availability, but we did not establish the terms of financing or the exact checkout total. Obtain a written schedule showing both the treatment period and every payment obligation.

The public service descriptions discuss medical evaluation, review of relevant laboratory information and an individualized plan. The site lists California and Arizona clinics, but we have not inferred nationwide access from its online pages. Confirm the location, telehealth eligibility and follow-up arrangement that apply where you are physically receiving care.

A separately marketed microdosing program describes different enrollment requirements. Its statements should not be generalized to every semaglutide or tirzepatide pathway. Ask the actual clinician which assessment is needed, how follow-up is arranged and who handles a medication concern. The ongoing-support guide helps separate administrative messages from clinical review.

The product FAQs describe self-pay care and suggest checking HSA or FSA eligibility. That does not establish reimbursement for a particular person or mean ordinary insurance covers the program. The company advertises a consistent price across doses within the selected offer; confirm what happens if the treatment plan, formulation or service changes.

We could reach the site’s return-policy, shipping-policy and agreement pages, but the checked public views did not expose substantive cancellation or refund provisions. We therefore cannot state a verified cancellation deadline or refund entitlement. This is a retrieval limitation, not proof that the company has no policy. Request the actual terms before making a recurring or prepaid purchase, especially what happens to unused prepaid treatment if prescribing stops.

The company’s pharmacy, testing and certification language does not identify and independently validate the pharmacy assigned to every patient. The advertised products are compounded. FDA explains that compounded drugs are not FDA approved and are not reviewed for safety, effectiveness and quality before marketing. We have not treated the company’s outcomes or product-quality claims as independently demonstrated findings.

iThriveMD is most useful to examine as a specific care arrangement with a particular clinic or clinical team, rather than a price card alone. Before buying, obtain the full payment schedule, service geography, dispensing-pharmacy details, clinical contact route and written cancellation policy. The price comparison remains incomplete until the 28-day calendar and prepaid commitment are understood alongside the care the patient can actually access.